Hormonal
Tirzepatide 15 mg and semaglutide 1.0 mg, when added to metformin in type 2 diabetes, provide superior HbA1c reduction and weight loss compared to other GLP-1 receptor agonists, without increasing hypoglycemia risk.
For patients with Type 2 Diabetes on Metformin, Tirzepatide 15mg and Semaglutide 1.0mg are the most effective options for lowering blood sugar and losing weight among GLP-1 agonists. They do not increase hypoglycemia risk. If injections are a barrier, oral Semaglutide 14mg is a viable alternative with good efficacy.
According to the NMA, tirzepatide 15 mg, semaglutide 1.0 mg... reduced HbA1c by -2.23%, -1.57%... and body weight by -11.33 kg, -5.99 kg... All GLP-1RA did not lead to increased incidence of hypoglycemia.
Why this rating
Network meta-analysis of 34 RCTs with 12,993 patients.
Source
Comparison of the efficacy and safety of 10 glucagon-like peptide-1 receptor agonists as add-on to metformin in patients with type 2 diabetes: a systematic review
Zeyu Xie et al. · Frontiers in Endocrinology · 2023
DOI 10.3389/fendo.2023.1244432
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →